Patents Assigned to Amgen
  • OVEREXPRESSION OF N-GLYCOSYLATION PATHWAY REGULATORS TO MODULATE GLYCOSYLATION OF RECOMBINANT PROTEINS
    Publication number: 20200277642
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Applicant: AMGEN INC.
    Inventors: Shivani GUPTA, Sohye KANG
  • Liquid formulation comprising GM-CSF neutralizing compound
    Patent number: 10758621
    Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 1, 2020
    Assignees: Amgen Research (Munich) GmbH, Takeda GmbH
    Inventors: Thomas Urbig, Thomas Boehm, Wolfram Steinhilber, Michael Molhoj
  • Drug delivery system with temperature-sensitive control
    Patent number: 10758683
    Abstract: A drug delivery system includes a reservoir and a drug delivery device coupled to the reservoir. The drug delivery device also may include at least one temperature-sensitive component and a lock having locked and unlocked states. The system further includes an output device, and a controller coupled to the lock and the output device. The controller may also include a temperature sensor, or may be coupled to the temperature sensor. The controller is programmed or configured to determine if the temperature of a drug in the reservoir or of the temperature-sensitive component exceeds an upper limit or is below a lower limit, and to activate the lock in either event. The controller is also programmed or configured to determine, directly or indirectly, if the temperature subsequently is between the upper and lower limits, and to unlock lock as a consequence.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: September 1, 2020
    Assignee: AMGEN INC.
    Inventors: Scott R. Gibson, Mark Ka Lai Lee, Donald Busby, Stephanie Toy, Suhas Krishna, Francisca Tan-Malecki, Ferry Tamtoro
  • Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
    Patent number: 10752664
    Abstract: Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: August 25, 2020
    Assignee: AMGEN INC.
    Inventors: YuMei Xiong, Yang Li, Wen-Chen Yeh, Bei Shan, Jackie Zeqi Sheng
  • Binding molecules for BCMA and CD3
    Patent number: 10752694
    Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of the binding molecule and a kit comprising the binding molecule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 25, 2020
    Assignee: Amgen Inc.
    Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20200255496
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEG-FR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 13, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Triazole furan compounds as agonists of the APJ receptor
    Patent number: 10736883
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Brown, Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Jonathan Houze, Frank Kayser, Aarif Yusuf Khakoo, David j. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Wen-Chen Yeh
  • PAC1 antibodies and uses thereof
    Patent number: 10738110
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • MACROCYCLIC COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200247821
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 27, 2018
    Publication date: August 6, 2020
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
  • Alkynyl dihydroquinoline sulfonamide compounds
    Patent number: 10729684
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 4, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Karina R. Vaida
  • KIF18A INHIBITORS
    Publication number: 20200239441
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
  • Autoinjector with shock reducing elements
    Patent number: 10722655
    Abstract: An injection device, method, and system for drug delivery includes a primary container for storing a drug, the container having a stopper movably disposed in the container for expelling the drug, an injection drive mechanism comprising a plunger for acting on the stopper and an energy source for exerting a force on the plunger to cause the plunger to act on the stopper to expel the drug, the force causing the plunger to accelerate to a velocity prior to acting on the stopper, and a damping mechanism for reducing the velocity of the plunger prior to acting on the stopper. The damping mechanism can include a dashpot or an energy absorbing material associated with the plunger. Alternatively or additionally, the damping mechanisms can include absorbing material disposed between support members of an outer casing of the injection device and the primary container.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: July 28, 2020
    Assignee: AMGEN INC.
    Inventors: Christopher Folk, Scott R. Gibson
  • Bisamide sarcomere activating compounds and uses therof
    Patent number: 10723720
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 28, 2020
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • CYCLOPROPYL FUSED THIAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    Publication number: 20200231585
    Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I) wherein variables A, R1, R2, R2?, R3, R4, and R5 of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 23, 2020
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, Jian J. CHEN, Michael J. FROHN, Paul E. HARRINGTON, Jonathan D. LOW, Vu V. MA, Thomas T. NGUYEN, Alexander PICKRELL, Corey REEVES
  • 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    Publication number: 20200231601
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2?, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 23, 2020
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Matthew P. BOURBEAU, James A. BROWN, Ning CHEN, Michael J. FROHN, Zice FU, Longbin LIU, Qingyian LIU, Liping H. PETTUS, Wenyuan QIAN, Corey REEVES, Aaron C. SIEGMUND
  • Drug delivery device with a rotatable drive mechanism
    Patent number: 10709845
    Abstract: A rotatable drive mechanism for a drug delivery device may include a lead screw having a distal end, a proximal end, and external threads, a bearing, and a ball screw driver having a threaded aperture wherein the threaded aperture is configured to rotatably engage with the external threads of the lead screw. The mechanism may further include a biasing device disposed between the bearing and the ball screw driver generating an axial drive force, and an activation device configured to release the biasing device and allowing the biasing device to expand from a compressed position to an extended position through which the axial drive force of the biasing device causes the ball screw driver to axially move toward the distal end of the lead screw and rotate the lead screw such that a threaded engagement between the lead screw and the ball screw driver bears the axial drive force.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 14, 2020
    Assignee: AMGEN INC.
    Inventor: Steve Sanchez
  • Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
    Publication number: 20200216546
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: January 16, 2020
    Publication date: July 9, 2020
    Applicant: Amgen, Inc.
    Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna ARORA
  • OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    Publication number: 20200207747
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2?, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (A?) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 2, 2020
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Matthew P. BOURBEAU, Ning CHEN, Michael J. FROHN, Paul E. HARRINGTON, Qingyian LIU, Corey REEVES
  • Handheld drug delivery device
    Patent number: D891612
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 28, 2020
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Ryan Jerome Ramos, Christian Plambech, Claus Jepsen, Emil Wegger Jensen
  • Vial sleeve
    Patent number: D894423
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 25, 2020
    Assignee: AMGEN INC.
    Inventors: Anthony Bantug, Wael Mismar, Kenneth Tan, Tark Abed, Justin Allen Marsh, Mario Bogdan, Scott Comiso